Monthly Archives: March 2011

Fact Versus Fact: When Will the Numbers Add Up?

By Jennifer Ringler | Published: March 15, 2011
An ongoing debate has journalists, investment analysts, pharma companies, government officials, and economists all stating the “facts” about the cost of new drug R&D. But if the numbers and data are indisputable, why are there two opposing conclusions? The debate is worth watching, given the growing view that the industry’s business model—based on extensive [...]
Posted in Strategy | 3 Comments

New Head of EFPIA Lined Up

By Julian Upton | Published: March 9, 2011
As the European Medicines Agency searches for a new head amidst rumbles of disquiet over the recently departed Thomas Lönngren’s new role, Europe looks set to fill another high profile vacancy with the appointment of Richard Bergstrom as President of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Although EFPIA has yet to officially announce [...]
Posted in Europe, leadership | Tagged , , , | Leave a comment

'Freedom of Thought' Key to Middle East Science Progress

By Jennifer Ringler | Published: March 9, 2011
A new report from Thomson Reuters points to a “rapidly changing context for science and innovation in the Middle East.” The Arabian, Persian and Turkish Middle East may currently produce only 4% of the world’s scientific literature, but the output is growing rapidly, according to a new Global Research Report from Thomson Reuters. Indeed, countries such [...]
Posted in Emerging Markets, Global | Tagged , , , , , , , | Leave a comment

Regulator Move Re-Opens Arguments over European Transparency

By Julian Upton | Published: March 9, 2011
At the end of last month, European public health and transparency campaigners sent a letter to EC health commissioner John Dalli, outlining their concerns about former EMA head Thomas Lönngren’s recent career move. The Alliance for Lobbying Transparency and Ethics Regulation (ALTER-EU), Health Action International (HAI) Europe, the International Society of Drug Bulletins (ISDB) — and [...]
Posted in Europe, Global, Regulatory | Tagged , , , , , | Leave a comment